Xpert MTB/RIF检测在美国疑似肺结核住院患者中的临床影响与成本效果
该前瞻性观察队列研究纳入美国西雅图一家公立医院318例符合空气隔离条件的疑似肺结核住院患者,比较5种检测策略的性能、临床效用与机构成本效果。结果显示一次Xpert检测最具有成本效果,可在不降低敏感性的情况下减少空气隔离时间并节省费用。
要点
- 一次Xpert对培养的敏感性为0.85,与涂片镜检相当或更优。
- 一次Xpert策略最具成本效果,在愿意支付50000美元时99.9%被优先选择。
- Xpert可平均节省51.5患者小时的空气隔离时间并最多节省11466美元。
核心结论
- 在低负担地区的疑似肺结核住院患者中,核酸扩增检测可减少空气隔离时间,敏感性相当、特异性更高且比涂片镜检更具成本效果。
研究设计与样本
- 每例患者痰标本进行涂片镜检、培养、药敏试验和核酸扩增检测,比较5种检测策略的性能、临床效用与机构成本效果。
主要发现
- 318例疑似肺结核住院患者中20例(6.3%)培养阳性为结核分枝杆菌。
- 一次Xpert检测单个未浓缩痰标本(假设未浓缩与浓缩痰结果等效)是最具成本效果的策略,在愿意支付50000美元时99.9%被优先选择。
- 该策略相对涂片镜检平均节省51.5患者小时的空气隔离时间并最多节省11466美元,且不降低敏感性。
关键数值与推荐
- 一次Xpert策略在愿意支付50000美元时99.9%被优先选择,平均节省51.5患者小时空气隔离时间和最多11466美元。
临床怎么用
- 在低负担地区疑似肺结核住院患者中,可考虑用一次Xpert检测未浓缩痰标本替代涂片镜检以指导空气隔离决策。
- 该策略可在不降低敏感性的前提下缩短空气隔离时间并降低机构成本。
局限性
- 研究为单中心前瞻性观察队列,样本来自美国西雅图一家公立医院。
- 成本效果分析基于机构视角,且假设未浓缩与浓缩痰标本的Xpert结果等效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Microscopic examination of acid-fast-stained sputum smears is the current standard of care in the United States to determine airborne infection isolation (AII) of inpatients with presumptive pulmonary tuberculosis (PTB). However, nucleic acid amplification testing (NAAT) with the Xpert MTB/RIF assay (Xpert) may be more efficient and less costly. METHODS: This prospective observational cohort study enrolled a consecutive sample of 318 AII-eligible inpatients from a public hospital in Seattle, Washington, from March 2012 to October 2013. Sputum samples were collected from each inpatient and analyzed using smear microscopy, culture, drug susceptibility testing, and NAAT. The performance, clinical utility (AII duration and survival), and cost-effectiveness from an institutional perspective were compared for 5 testing strategies. RESULTS: Among the 318 admissions with presumptive PTB, 20 (6.3%) were culture-positive for Mycobacterium tuberculosis. The sensitivity of 1 Xpert, 2 Xperts, 2 smears, or 3 smears compared to culture was 0.85 (95% confidence interval [CI], .61–.96), 0.95 (95% CI, .73–1.0), 0.70 (95% CI, .46–.88), and 0.80 (95% CI, .56–.93), respectively. A cost-effectiveness analysis of the study results demonstrated that an Xpert test on 1 unconcentrated sputum sample (assuming equivalent results for unconcentrated and concentrated sputum samples) is the most cost-effective strategy (99.9% preferred at willingness-to-pay of US$50000) and on average would save 51.5 patient-hours in AII and up to $11466 relative to microscopy without a compromise in sensitivity. CONCLUSIONS: In hospitalized patients with presumptive PTB in a low-burden setting, NAAT can reduce AII and is comparably sensitive, more specific, and more cost-effective than smear microscopy.
引用
- Cowan JF, Chandler AS, Kracen E, et al. Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States. Clin Infect Dis. 2017. PMID: 28172666. doi:10.1093/cid/ciw803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。